The use of radionuclides in medicine is based largely on the discoveries of two critical
concepts, the “tracer principle” and the “magic bullet”. In 1913, George de Hevesy …

Antibodies have proven to be effective agents in cancer imaging and therapy. One of the
major challenges still facing the field is the heterogeneous distribution of these agents in …

Several monoclonal antibodies are now approved for cancer therapy, such as rituximab, an
anti-CD20 monoclonal antibody for the treatment of B-cell non-Hodgkin's lymphoma …

The use of monoclonal antibodies to deliver radioisotopes directly to tumor cells has
become a promising strategy to enhance the antitumor effects of native antibodies. Since the …

In lymphoid malignancies and in certain solid cancers such as medullary thyroid carcinoma,
somewhat mixed success has been achieved when applying radioimmunotherapy (RIT) with …

Monoclonal antibodies have become a viable strategy for the delivery of therapeutic, particle
emitting radionuclides specifically to tumor cells to either augment anti-tumor action of the …

Abstract Astatine-211 (211 At, t 1/2= 7.21 h) emitting two α particles with energies of 5.87
and 7.45 MeV, can lead to a high linear energy transfer (LET= 98.84 keV/µm) and short …

There is a wide range of potential applications of inorganic compounds, and metal
coordination complexes in particular, in medicine but progress is hampered by a lack of …

Radionuclide therapy is a promising modality for treatment of tumours of haematopoietic
origin while the success for treatment of solid tumours so far has been limited. The authors …

Abstract Purpose The PET tracer, 124 I-cG250, directed against carbonic anhydrase IX
(CAIX) shows promise for presurgical diagnosis of clear-cell renal cell carcinoma …